Prognostic value of albumin-bilirubin grade in patients with pancreatic cancer: A systematic review and meta-analysis.

IF 2.5 Q3 GASTROENTEROLOGY & HEPATOLOGY

Indian Journal of Gastroenterology Pub Date : 2026-10-01 Epub Date: 2026-03-08 DOI:10.1007/s12664-025-01945-7

Mahyaar Omouri-Kharashtomi, Mohammad Mohammadi, Iman Menbari Oskouie, Faraz Mahdizadeh, Amir Anushiravani

{"title":"Prognostic value of albumin-bilirubin grade in patients with pancreatic cancer: A systematic review and meta-analysis.","authors":"Mahyaar Omouri-Kharashtomi, Mohammad Mohammadi, Iman Menbari Oskouie, Faraz Mahdizadeh, Amir Anushiravani","doi":"10.1007/s12664-025-01945-7","DOIUrl":null,"url":null,"abstract":"Background: With a five-year survival rate near 10%, pancreatic cancer is among the cancers with poor survival. Understanding the prognostic factors provides clinical insights for better decision-making. This meta-analysis aims to assess the prognostic value of the albumin-bilirubin (ALBI) grade in patients with pancreatic cancer.Method: A comprehensive search using \"pancreatic cancer\" and \"ALBI grade\" as keywords was conducted on the PubMed, Web of Science, Embase and Scopus until August 14, 2025. Studies investigating the prognostic value of the ALBI grade in patients with pancreatic cancer were included. The prognostic value was assessed through the hazard ratio (HR) with a 95% confidence interval (95% CI). The meta-analysis was performed using R version 4.2.3.Results: The meta-analysis comprised six studies with 1665 patients for overall survival (OS) analysis and three studies with 936 patients for recurrence-free survival/disease-free survival (RFS/DFS). A higher ALBI grade was associated with decreased OS in patients with pancreatic cancer (HR = 2.14, 95% CI [1.53, 3.00]). A higher ALBI grade was associated with decreased RFS/DFS (HR = 2.39, 95% CI [1.02, 5.58]). A sub-group analysis based on ALBI grade revealed that no significant differences between different grading approaches (high vs. low, 2 vs. 1 and 3 vs. 1) were observed in predicting OS.Conclusion: A higher ALBI grade was significantly associated with decreased OS and RFS/DFS in patients with pancreatic cancer. The ALBI grade could be considered a reliable prognostic marker for clinical applications in patients with pancreatic cancer.","PeriodicalId":13404,"journal":{"name":"Indian Journal of Gastroenterology","volume":" ","pages":"816-827"},"PeriodicalIF":2.5000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Gastroenterology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12664-025-01945-7","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/3/8 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: With a five-year survival rate near 10%, pancreatic cancer is among the cancers with poor survival. Understanding the prognostic factors provides clinical insights for better decision-making. This meta-analysis aims to assess the prognostic value of the albumin-bilirubin (ALBI) grade in patients with pancreatic cancer.

Method: A comprehensive search using "pancreatic cancer" and "ALBI grade" as keywords was conducted on the PubMed, Web of Science, Embase and Scopus until August 14, 2025. Studies investigating the prognostic value of the ALBI grade in patients with pancreatic cancer were included. The prognostic value was assessed through the hazard ratio (HR) with a 95% confidence interval (95% CI). The meta-analysis was performed using R version 4.2.3.

Results: The meta-analysis comprised six studies with 1665 patients for overall survival (OS) analysis and three studies with 936 patients for recurrence-free survival/disease-free survival (RFS/DFS). A higher ALBI grade was associated with decreased OS in patients with pancreatic cancer (HR = 2.14, 95% CI [1.53, 3.00]). A higher ALBI grade was associated with decreased RFS/DFS (HR = 2.39, 95% CI [1.02, 5.58]). A sub-group analysis based on ALBI grade revealed that no significant differences between different grading approaches (high vs. low, 2 vs. 1 and 3 vs. 1) were observed in predicting OS.

Conclusion: A higher ALBI grade was significantly associated with decreased OS and RFS/DFS in patients with pancreatic cancer. The ALBI grade could be considered a reliable prognostic marker for clinical applications in patients with pancreatic cancer.

查看原文本刊更多论文

白蛋白胆红素分级在胰腺癌患者中的预后价值：一项系统回顾和荟萃分析。

背景：胰腺癌是生存率较低的癌症之一，其5年生存率接近10%。了解预后因素可以为更好的决策提供临床见解。本荟萃分析旨在评估白蛋白胆红素（ALBI）分级在胰腺癌患者中的预后价值。方法：以“pancreatic cancer”和“ALBI grade”为关键词，综合检索PubMed、Web of Science、Embase、Scopus，检索截止日期为2025年8月14日。研究调查胰腺癌患者ALBI分级的预后价值。通过95%可信区间（95% CI）的风险比（HR）评估预后价值。meta分析采用R 4.2.3版本。结果：荟萃分析包括6项研究，共1665例患者进行总生存（OS）分析，3项研究，共936例患者进行无复发生存/无病生存（RFS/DFS）分析。较高的ALBI分级与胰腺癌患者的OS降低相关（HR = 2.14, 95% CI[1.53, 3.00]）。较高的ALBI分级与降低的RFS/DFS相关（HR = 2.39, 95% CI[1.02, 5.58]）。基于ALBI评分的亚组分析显示，不同评分方法（高与低、2与1、3与1）在预测OS方面没有显著差异。结论：较高的ALBI分级与降低胰腺癌患者的OS和RFS/DFS显著相关。ALBI分级可被认为是胰腺癌患者临床应用的可靠预后指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Gastroenterology GASTROENTEROLOGY & HEPATOLOGY-

CiteScore

3.90

自引率

10.00%

发文量

期刊介绍： The Indian Journal of Gastroenterology aims to help doctors everywhere practise better medicine and to influence the debate on gastroenterology. To achieve these aims, we publish original scientific studies, state-of -the-art special articles, reports and papers commenting on the clinical, scientific and public health factors affecting aspects of gastroenterology. We shall be delighted to receive articles for publication in all of these categories and letters commenting on the contents of the Journal or on issues of interest to our readers.